Phibro Animal Health (NASDAQ:PAHC) (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment offers an array of vaccines and pharmaceutical products targeting poultry, swine, cattle and aquaculture. Mineral Nutrition provides trace mineral supplements and premix solutions to optimize feed formulations, while Performance Products focuses on feed additives that improve nutrient utilization, gut health and production efficiency. Phibro’s products are used by producers, integrators and veterinary professionals to address disease prevention, growth promotion and regulatory compliance in modern animal agriculture.
With operations spanning North America, Latin America, Europe, the Middle East, Africa and Asia-Pacific, Phibro serves customers in more than 70 countries. The company traces its roots to the mid-20th century and has grown through strategic acquisitions, internal research and global partnerships to build a comprehensive suite of animal health solutions. Under the leadership of its President and Chief Executive Officer, Norbert G. Schaefer, Phibro continues to invest in innovation, regulatory approvals and manufacturing capabilities to meet evolving industry needs and support sustainable food production worldwide.
